<DOC>
	<DOCNO>NCT02760615</DOCNO>
	<brief_summary>The purpose study evaluate step-wise approach disease drug-drug interaction ( DDI ) potential vedolizumab indirectly affect exposure cytochrome P-450 ( CYP ) substrate drug modulate pro-inflammatory cytokine participant ulcerative colitis ( UC ) Crohn 's disease ( CD ) treat vedolizumab .</brief_summary>
	<brief_title>Phase 4 , Vedolizumab-4002 Post-marketing , Disease-Drug-Drug Interaction Study</brief_title>
	<detailed_description>The drug test study call vedolizumab , test assess possibility drug-drug interaction administer medication . The study conduct 2 part . Part 1 enroll approximately 40 participant : 20 healthy participant 20 participant UC CD currently treat vedolizumab . All participant receive follow medication : - Caffeine 100 mg - Losartan 50 mg - Omeprazole 20 mg - Dextromethorphan 30 mg - Midazolam 2 mg Part 2 enroll approximately 20 participant establish vedolizumab intravenous ( IV ) maintenance treatment 300 mg every 8 week treatment UC CD . Participants receive medication dosage Part 1 addition schedule vedolizumab 300 mg IV . For Part 1 Subjects keep study unit Check-in ( Day -1 ) least 24 hour dose safety subject Part 1 study approximately 6 week , include Screening . subject Part 1 study approximately 6 week , include Screening . For Part 2 Subjects keep study unit Check-in ( Day -1 ) least 24 hour dose safety PK assessment discharge . The total confinement period 3 day . The total duration subject Part 2 study approximately 12 week , include Screening .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form require privacy authorization prior initiation study procedure include request participant fast laboratory evaluation . 3 . Is cytochrome P450 ( CYP ) 2C9 , CYP2C19 , CYP2D6 extensive metabolizer , base genotyping pharmacogenomic ( PGx ) deoxyribonucleic acid ( DNA ) analysis . 4 . Is male female age 18 55 year , inclusive , Screening . 5 . Weighs least 50 kg body mass index ( BMI ) 18.0 30 kg/m^2 , inclusive , Screening Checkin ( Day 1 ) . 6 . The healthy control participant Part 1 study match Day1 ulcerative colitis ( UC ) Crohn 's disease ( CD ) participants basis age ( ±10 year ) , gender weight ( ±30 % ) . 7 . Participants Part 2 matched UC CD participant Part 1 Day1 basis inflammatory bowel disease ( IBD ) diagnosis ( UC CD ) , age ( ±10 year ) , gender weight ( ±30 % ) . For Part 1 Participants : 8 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study . 9 . All female participant childbearing potential sexually active , agree routinely use adequate contraception signing inform consent throughout duration study . NOTE : Female participant NOT childbearing potential define surgically sterilize ( hysterectomy , bilateral oophorectomy , tubal ligation [ least 2 year postoperation ] ) . For Part 1 Only Participants UC CD 10 . Has diagnosis UC CD establish least 6 month prior enrollment clinical endoscopic evidence corroborate histopathology report . 11 . Prior enter study , participant UC must endoscopy screen confirm active disease , Mayo score 6 12 endoscopic subscore ≥2 . Participants CD must Crohn 's Disease Activity Index ( CDAI ) score 220 450 confirm moderate severe disease entry ( ie , Day1 ) . 12 . Participant may receive therapeutic dose follow drug treatment underlie disease : Oral topical 5aminosalicylic acid ( 5ASA ) compound provide dose stable 2 week immediately prior enrollment . Probiotics ( eg , Culturelle , Saccharomyces boulardii ) provide dose stable 2 week immediately prior enrollment . Antidiarrheals ( eg , loperamide , diphenoxylate atropine ) control chronic diarrhea . Azathioprine 6mercaptopurine , provide dose stable 8 week immediately prior enrollment . Methotrexate provide dose stable 8 week immediately prior randomization . 13 . Creactive protein ( CRP ) ≥5 mg/L screening period participant CD . For Part 1 Healthy Participants Only : 14 . The participant , opinion investigator , healthy condition determine prestudy physical examination , medical history , vital sign , electrocardiogram ( ECG ) , result blood biochemistry , hematology , serology , urinalysis test . For Part 2 Participants Active UC CD : 15 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 57 day last dose . 16 . All female participant childbearing potential sexually active nonsterilized male partner , agree routinely use adequate contraception Screening 57 day receive last dose study medication . NOTE : Female participant NOT childbearing potential define surgically sterilize ( hysterectomy , bilateral oophorectomy , tubal ligation [ least 2 year postoperation ] ) . 17 . Has diagnosis UC CD establish least 6 month prior enrollment clinical endoscopic evidence corroborate histopathology report . 18 . Is establish vedolizumab intravenous ( IV ) 300 mg every 8 week ( Q8W ) treatment UC CD clinical remission assess within 7 day dose defined UC ; A complete Mayo score ≤2 point individual subscore &gt; 1 point . For CD ; CDAI ≤150 point . 19 . Participant may receive therapeutic dose follow drug treatment underlie disease : Oral topical ASA compound provide dose stable 2 week immediately prior enrollment . Probiotics ( eg , Culturelle , S. boulardii ) provide dose stable 2 week immediately prior enrollment . Antidiarrheals ( eg , loperamide , diphenoxylate atropine ) control chronic diarrhea . Azathioprine 6mercaptopurine , provide dose stable 8 week immediately prior enrollment . Methotrexate provide dose stable 8 week immediately prior randomization . 1 . Has know hypersensitivity drug component Injection ( Inje ) Cocktail . 2 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 3 . Within 30 day prior enrollment , participant UC CD receive treatment underlie disease specifically list protocol Treatment UC CD . 4 . If female , participant pregnant lactate intend become pregnant , , within 57 day participate study ; intend donate ova time period . 5 . If male , participant intend donate sperm course study 57 day thereafter . 6 . Has receive rituximab natalizumab treatment integrin inhibitor . 7 . Has take exclude medication , supplement , food product list protocol . 8 . Has evidence abdominal abscess toxic megacolon initial Screening Visit . 9 . Has extensive colonic resection , subtotal total colectomy . 10 . Has ileostomy , colostomy , know fix symptomatic stenosis intestine . 11 . Has evidence treatment Clostridium difficile infection within 60 day intestinal pathogen within 30 day prior enrollment . 12 . Has history evidence adenomatous colonic polyp remove . 13 . Has history evidence colonic mucosal dysplasia . 14 . Has chronic hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . 15 . Has identify congenital acquire immunodeficiency ( eg , common variable immunodeficiency , human immunodeficiency virus [ HIV ] infection , organ transplantation ) . 16 . Has receive live vaccination within 30 day prior study drug administration except influenza vaccine . 17 . Has clinically significant infection ( eg , pneumonia , pyelonephritis ) within 30 day prior enrollment . 18 . Has unstable uncontrolled cardiovascular , pulmonary , hepatic , renal , gastrointestinal , genitourinary , hematological , coagulation , immunological , endocrine/metabolic , medical disorder , opinion investigator , would confound study result compromise participant safety . 19 . Has surgical procedure require general anesthesia within 30 day prior enrollment plan undergo major surgery study period . 20 . Has history malignancy , except follow : ( ) adequately treat nonmetastatic basal cell skin cancer ; ( b ) squamous cell skin cancer adequately treat recur least 1 year prior enrollment ; ( c ) history cervical carcinoma situ adequately treat recur least 3 year prior enrollment . Participants remote history malignancy ( eg , &gt; 10 year since completion curative therapy without recurrence ) consider base nature malignancy therapy receive must discuss sponsor casebycase basis prior enrollment . 21 . Has use nicotinecontaining product ( include limit cigarette , electronic cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 1 ) . Cotinine test positive Screening Checkin ( Day 1 ) . 22 . Has current recent history ( within 1 year prior enrollment ) alcohol dependence illicit drug use . 23 . Has active psychiatric problem , investigator 's opinion , may interfere compliance study procedure . 24 . Is unable attend study visit comply study procedure . For Part 1 Participants With UC CD : 25 . Has receive investigational approve biologic biosimilar agent last 6 month prior Screening . 26 . Participant currently require anticipated require surgical intervention UC CD study . For Part 1 Healthy Participants Only : 27 . Has laboratory abnormality consider clinically significant investigator Screening Period , example following : Hemoglobin level &lt; 10 g/dL . White blood cell ( WBC ) count &lt; 3 x 10^9/L . Lymphocyte count &lt; 0.5 x 10^9/L . Platelet count &lt; 100 x 10^9/L &gt; 1200 x 10^9/L . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; upper limit normal ( ULN ) . Alkaline phosphatase &gt; ULN . Serum creatinine &gt; 1.5 x ULN . For Part 1 Participants UC CD Part 2 Participants : 28 . Has follow laboratory abnormality consider clinically significant investigator Screening Period : Hemoglobin level &lt; 8 g/dL . WBC count &lt; 3 x 10^9/L . Lymphocyte count &lt; 0.5 x 10^9/L . Platelet count &lt; 100 x 10^9/L &gt; 1200 x 10^9/L . ALT AST &gt; 3 x ULN . Alkaline phosphatase &gt; 3 x ULN . Serum creatinine &gt; 2 x ULN . For Part 2 : 29 . Has receive investigational approve biologic biosimilar agent vedolizumab last 6 month prior Screening . 30 . The subject active latent tuberculosis ( TB ) , may involve documentation patient 's TB status prior commence vedolizumab patient 's treating physician . 31 . Has history major neurological disorder , include stroke , multiple sclerosis , brain tumor , neurodegenerative disease . 32 . Has positive progressive multifocal leukoencephalopathy ( PML ) subjective symptom checklist screen prior dose Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>